

Dear Customer,

In preparation for the 2019-2020 influenza season, we are writing to provide you with an update on influenza vaccine formulation and production that will impact when you receive your vaccine.

Each year, the World Health Organization (WHO) and U.S. Food and Drug Administration (FDA), with help from epidemiologists around the world, select the virus strains to be included in influenza vaccines for the upcoming season. This year, due to late-emerging A/H3N2 viruses that circulated globally, the WHO and FDA decided to delay selection of the A/H3N2 strain by one month. This allowed health authorities to collect additional data to help improve the match of the vaccine strain to the A/H3N2 strain anticipated to circulate during the 2019-2020 season.

Sanofi Pasteur fully supports this decision by health authorities to collect additional data and make a more informed selection. However, as a result of the delay we anticipate that delivery of our influenza vaccines will be approximately 3-4 weeks behind the shipping commitments previously communicated. Sanofi Pasteur fully expects to manufacture and deliver every dose reserved by our customers, beginning with partial shipments to all customers in late-August or September, with all shipments completed by the end of November.

We at Sanofi Pasteur take seriously our shared goal to help protect as many people as possible from influenza. Part of this commitment is to provide useful information at this early stage to help ensure that the delay in vaccine delivery does not result in fewer people being vaccinated this coming season. We hope this will give you time to plan any necessary changes to your immunization efforts and that sharing the reason for the delay will help you maintain your patients' confidence in influenza vaccination.

If you have any questions, please contact your Sanofi Pasteur representative or call 1-800-VACCINE (1-800-822-2463)

Sincerely,



Elaine O'Hara  
Chief Commercial Officer  
Sanofi Pasteur US